The global artificial tears market is expected to register a valuation of USD 3.4 billion in 2024 and further expand at a CAGR of 5.4% to reach a valuation of USD 5.8 billion by 2034. According to Future Market Insights, glycerine tears are leading the market with a share of about 26.7% in 2024 within the global artificial tears market size.
| Data Points | Market Insights |
|---|---|
| Artificial Tears Market Value 2023 | USD 3.3 billion |
| Artificial Tears Market Value 2024 | USD 3.4 billion |
| Artificial Tears Market Value 2034 | USD 5.8 billion |
| Artificial Tears Market CAGR | 5.4% |
Artificial tears eye drops keep the outer layer of the eyes wet. The market for artificial tears has experienced substantial growth due to the increasing need for greasing eye products in ophthalmic therapy. An increasing percentage of people suffer from dry eye syndrome, which might open up lucrative new markets for artificial tears.
Artificial tears are used to moisten contact lenses, examinations, and routine eye check-ups. The market is expanding due to the rise in eye and post-eye surgeries
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The artificial tears market is exponentially growing due to government initiatives and awareness of dry eye syndrome. Rising rates of dry eye disease and the geriatric population fuel the market's expansion
The National Programme for Control of Blindness (NPCB) and other government programs are increasing public awareness through pharmaceuticals and distribution networks. Furthermore, the need for eye care products and the availability of eye drops to treat eye disease is likely to boost the artificial tears market online.
Artificial tear brands in the global market for artificial tears are competing for market share by acquiring local and small manufacturing. Manufacturers are implementing advertising and social media initiatives to increase the company's sales and market share to promote their products in the marketplace.
Product safety concerns that result in restricting the use of artificial tears products. Additionally, some safety issues with teardrops include the risk of contamination and unfavorable reactions to the preservatives used in the product. The usage is restricted due to safety concerns, and the various eye-related conditions may lead to reduced productivity, negatively influencing the quality of life.
The adverse effects such as eye irritation, eye pain, blurred vision, red eyes, and foreign body sensation in the eyes are undoubtedly challenging the market's expansion. Furthermore, the need for artificial tears is being constrained by developing several drugs that can reduce the irritation caused by dry eye syndrome. Certain restrictions are anticipated to lead to reduced demand for artificial tears, which would, in turn, limit artificial tears market expansion.
Principal Consultant
The sale of artificial tears expanded at a CAGR of 5.0% from 2019 to 2023, owing to the rising dry eye syndrome and increasing pollution rate.
Artificial tears are lubricant eye drops used to reduce the dryness and irritation caused by keratoconjunctivitis sicca. These products, also known as ocular lubricants, are built explicitly to irritate and relieve burning and discomfort caused by dry eyes. Long-term computer use, fatigue, dry and smoky weather, and other reasons can all contribute to dry eyes.
The Dry Eye Directory represents statistics; currently, dry eyes affect between 16 and 49 million Americans. It means 5 to 15% of the total population, and according to a Gallup Poll, 29 million Americans are likely to suffer from dry eye disease by 2034.
The sales of artificial tears in the market are expected to rise during the forecast period due to excessive eye drops and lubrication demand. With the abovementioned factors, the global market is expected to grow 5.4% during the forecast period.
| Country/region | CAGR (2024 to 2034) |
|---|---|
| United States | 6.7% |
| China | 10.2% |
| India | 4.7% |
The United States is estimated to hold a CAGR of 6.7% of the global market through 2034. The United States artificial tears market currently sees several pharmaceutical manufacturers collaborating with eye care solution providers to deliver high-quality products for commercial use.
To increase the impact of manufacturing position on the global market, the industry's players are concentrating on promoting their brands and consolidating supply chain distribution networks in the United States.
India is set to exhibit a growth rate of nearly 4.7% ;in the artificial tears market through 2034. In India, cases of dry eye syndrome are increasing rapidly. For instance, in July 2020, a report published by the Indian Journal of Ophthalmology, a study from north India estimated that dry eye disease (DED) is 32% in north India, and 81% of cases were classified as severe DED based on symptoms.
Growing Prevalence of Eye Disorders Upsurge China Artificial Tears Market
China is likely to secure a 10.2% CAGR in the global artificial tears market by 2034, owing to the prevalence of dryness in the eyes and ocular surface irritation
One of the world's rapidly growing aging populations is in China. For instance, records stated by the World Health Organization (WHO), By 2040, it is anticipated that 28% of China's population will be over 60. A significant increase in the country's senior population has led to China experiencing substantial growth in the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Glycerine tears are expected to present a growth of 4.5% by the end of the forecast period, with a market share value of 26.4% by the end of 2024. Glycerine tears help to decrease symptoms of dry eyes, keep the eye moist, and help to protect the eye from injury.
| Product Type | Glycerine |
|---|---|
| CAGR (2024 to 2034) | 4.5% |
Solutions hold an artificial tears market share of 29.2% in 2024 and are expected to grow gradually over the forecast period, with an estimated CAGR of ;5.0%. Generally, artificial tear solutions help maintain moisture and lubricate dry eyes on the outer surfaces of the eyes. These eye drops can be used to treat aging-related dry eyes.
| Dosage Form | Solution |
|---|---|
| CAGR (2024 to 2034) | 5.0% |
Non-preservative-based formulation holds a prominent market share value of 55.2% in 2024, a CAGR of 5.6% by the end of the forecast period. Non-preservative eye drops do not contain any preservatives to stop the growth of bacteria. Non-preservative eye drops are available for three days (inpatients) or seven days (outpatients) in various application containers.
| Formulation | Non-preservative-based Formulation |
|---|---|
| CAGR (2024 to 2034) | 5.6% |
Dry eye syndrome holds a market share of 34.2% in 2024 and is expected to display gradual growth over the forecast period, with an estimated CAGR of 5.4% in 2034. Dry eye syndrome is caused due to autoimmune disease, hormone changes, allergic eye disease, or inflamed eyelid glands. Increased tear evaporation or decreased tear production caused by dry eyes syndrome holds a prominent position in the indication segment of the artificial tear market.
| Indication | Dry Eye Syndrome |
|---|---|
| CAGR (2024 to 2034) | 5.4% |
Retail pharmacies hold a prominent market share value of 38.0% in 2024, with a CAGR of 4.6% through 2034. Retail pharmacy stores have various products of different brands and can be easily located near residential areas, hence gaining a prominent position in the artificial tears market.
| Distribution Channel | Retail Pharmacies |
|---|---|
| CAGR (2024 to 2034) | 4.6% |
The market for producing artificial tears is fragmented, with several competitors. These businesses employ collaborations, partnerships, mergers and acquisitions, and new product releases to satisfy consumer demand and increase their client base. Various key players are launching types of artificial tears eye drops to upsurge the global artificial tears market size.
Recent Developments in the Artificial Tears Market
| Attribute | Details |
|---|---|
| Forecast Period | 2019 to 2023 |
| Historical Data Available for | 2024 to 2034 |
| Market Analysis | USD billion for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania and Middle East & Africa |
| Key Countries Covered | The United States, Canada, Brazil, Mexico, Argentina, The United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, South Africa and North Africa |
| Key Market Segments Covered | Ingredients, Dosage Form, Route of Administration, Indication, Distribution Channel, and Region |
| Key Companies Profiled | AbbVie, Inc.; Akorn, Inc.; Alcon; Bausch & Lomb; Johnson & Johnson; Eyevance Pharmaceuticals LLC; Ocusoft; I- MED PHARMA; Santen Pharmaceutical Co. Ltd; Similasan Corporation; Sun Pharmaceutical Industries Ltd; Ursapharm Arzneimittel GmbH; Novartis International AG; AFT Pharmaceuticals; Allergan plc; Rohto Pharmaceutical Co., Ltd; VISUfarma; Otsuka Pharmaceutical Co., Ltd.; NovaMedica LLC; ENTOD Research Cell UK Ltd; OASIS Medical, Inc; Abbott Medical Optics Inc |
| Pricing | Available upon Request |
The global artificial tears market is worth USD 3.4 billion in 2024 and is set to expand 1.7X over the next ten years.
Rising awareness about dry eye syndrome and adoption rate of artificial tears.
The United States, China, and the United Kingdom are expected to drive demand for the artificial tears market.
The artificial tears market is expected to reach a sales revenue to register a 5.4% CAGR.
The United States, India, and China are the key producers of artificial tears.
The United States accounted for a CAGR of 6.7% in the artificial tears market through 2034.
From 2019 to 2023, the market for artificial tears expanded by 5.0%.
India accounts for a CAGR of 4.7% in the global market during the forecast period.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Demand Value or Size (in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product 7.1. Glycerin Tears 7.2. Cellulose Tears 7.3. Oil-based Emulsion Tears 7.4. Polyethylene Glycol Based Tears 7.5. Sodium Hyaluronate Based Artificial Tears 7.6. Propylene Glycol Based Tears 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Dosage Form 8.1. Solution 8.2. Ointment 8.3. Emulsion 8.4. Gel 8.5. Spray 8.6. Suspensions 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Formulation 9.1. Preservative Based 9.2. Non-Preservative Based 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication 10.1. Dry Eye Syndrome 10.2. Allergies 10.3. Infections 10.4. UV & Blue Light Protection 10.5. Contact Lens Moisture Retention 10.6. Others 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 11.1. Retail Pharmacies 11.2. Hospital Pharmacies 11.3. Online Pharmacies 11.4. Ophthalmic Stores 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. East Asia 12.5. South Asia 12.6. Oceania 12.7. Middle East and Africa (MEA) 13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18. Oceania Market 2017 to 2022 and Forecast 2023 to 2033 19. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 20. Market Structure Analysis 21. Competition Analysis 21.1. AbbVie, Inc. 21.2. Akorn, Inc. 21.3. Alcon 21.4. Bausch & Lomb 21.5. Johnson & Johnson 21.6. Eyevance Pharmaceuticals LLC 21.7. Ocusoft 21.8. I-MED PHARMA 21.9. Santen Pharmaceutical Co. Ltd 21.10. Similasan Corporation 21.11. Sun Pharmaceutical Industries Ltd 21.12. Ursapharm Arzneimittel GmbH 21.13. Novartis International AG 21.14. AFT Pharmaceuticals 21.15. Allergan plc 21.16. Rohto Pharmaceutical Co., Ltd 21.17. VISUfarma 21.18. Otsuka Pharmaceutical Co., Ltd. 21.19. NovaMedica LLC 21.20. ENTOD Research Cell UK Ltd 21.21. OASIS Medical, Inc 21.22. Abbott Medical Optics Inc 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Artificial Tears Market
